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Abstract 
 
Background: Eosinophilic esophagitis (EoE) is a chronic, immune/antigen-mediated 
disease characterized by symptoms related to esophageal dysfunction and an 
eosinophil-predominant inflammation. This study has aimed to investigate whether 
the recently observed sensitization to Candida albicans in EoE patients is owing to 
pre-existing disease and its underlying abnormal epithelial barrier or, alternatively, is 
linked to corticosteroid (CS) therapy. 
Methods: Medical histories, as well as serum and tissue samples of 60 EoE patients 
(15 CS-naive, 45 with current or previous CS therapy) and 20 controls, stored in the 
Swiss Eosinophilic Esophagitis Database (SEED) and Biobank, were analyzed. We 
applied ImmunoCAP to measure IgE levels and immunofluorescence techniques to 
examine epithelial barrier components.  
Results: EoE patients had higher total IgE levels and were more frequently 
sensitized to Candida albicans than controls. In EoE tissue specimens, increased 
numbers of eosinophils and mast cells, a higher expression levels of thymic stromal 
lymphopoietin (TSLP), cathelicidin, proteases, i.e. the kallikreins (KLK)-5 and KLK-7, 
were observed as compared with controls, while reduced expression of lympho-
epithelial Kazal-type-related inhibitor (LEKTI), filaggrin, E-cadherin, claudin, occludin, 
demoglein-1 was found, independent of CS therapy. In CS-treated EoE, significantly 
lower numbers of CD1a+ cells and cathelicidin expression were noted as compared 
to CS-naive EoE. 
Conclusion: This study provides further evidence that EoE is associated with an 
abnormal epithelial barrier and postulates that CS therapy, by reducing innate 
immune mechanisms, may promote Candida albicans colonization and likely 
subsequent sensitization. 
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Abbreviations 
CS, corticosteroids; EoE, eosinophilic esophagitis; HBD, human beta-defensin, Ig, 
immunoglobulin; KLK, kallikrein; LEKTI, lympho-epithelial Kazal-type-related 
inhibitor; LHC, Langerhans cell; PAR2, protease-activated receptor; TSLP, thymic 
stromal lymphopoietin  
 
A recent consensus paper on eosinophilic esophagitis (EoE) attached particular 
significance to antigen-driven immunologic processes involving multiple pathogenic 
pathways and proposed a conceptual disease definition (1). EoE represents a 
chronic, immune/antigen-mediated disease characterized by symptoms related to 
esophageal dysfunction and exhibits an eosinophil-predominant inflammation on 
histology (1). An association of EoE with atopic diseases such as allergic rhinitis, 
bronchial asthma and atopic dermatitis has repeatedly been reported (2-4). The 
observations that IgE sensitization to environmental, including food allergens, is 
detected in most EoE patients (5, 6) and that EoE improved clinically and 
histologically upon food elimination diets (7) suggested a food-allergic disease. 
Recent research, however, has provided evidence that EoE should not be equated 
with an immunoglobulin (Ig)E–mediated allergy since the pathogenic mechanisms 
seem to be more complex, involving both innate and adaptive immune responses 
(8). In addition to food allergens, specific IgE to Candida albicans have frequently 
been observed in pediatric and adult EoE patients (5, 6). Although the pathogenic 
role of Candida albicans in EoE is uncertain, these findings raised the question of 
what drives the allergic sensitization.  
Disturbed epithelial barrier function seems to play a crucial role in the 
pathogenesis of EoE. In this way, antigens might penetrate the epithelium and 
initiate inflammatory responses and systemic sensitization. Several components of 
both tight and adherens junctions, as well as desmosomes, are engaged in 
constructing the epithelial barrier that is further supplemented by an immunological 
barrier (9, 10). In EoE patients, an abnormal expression of epithelial cell proteins 
mainly those involved in adhesion and integrity, such as desmogleins, claudins, 
cadherins, occludin, filaggrin and keratins as well as antimicrobial peptides and 
protease inhibitors, has been reported to be associated with esophageal 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
inflammation (11-15). Esophageal infections with Candida albicans have frequently 
been observed in patients with long-lasting dysphagia (16). Moreover, the use of 
swallowed corticosteroids (CS) predisposes patients with EoE for infections of the 
oral cavity with Candida albicans (17). So far, it is not clear whether Candida 
albicans colonization and sensitization is the consequence of an epithelial 
dysfunction associated with the disease and/or is a consequence of the treatment 
with CS that is the first line therapy for EoE.  
In this study, we aimed at investigating the specific IgE response to Candida 
albicans in EoE patients with and without recent CS therapy, and evaluating a variety 
of components forming the epithelial barrier in order to gain information on its 
composition as linked to CS therapy in EoE.  
 
 
Methods 
Patients 
Medical histories, as well as serum and tissue samples of 60 patients with EoE 
verified according to international criteria (1) and 20 controls without esophageal 
disease who were undergoing diagnostic endoscopy were obtained from the Swiss 
Eosinophilic Esophagitis Database (SEED) and Biobank. The patients’ 
characteristics are given in table 1. Patients with EoE were assigned to two groups: 
1. Active EoE without previous topical or systemic CS therapy (EoE naive; n=15), 2. 
EoE with current or previous CS therapy (EoE CS-treated; n=45). For evaluating 
epithelial barrier markers, we further stratified according to patients currently under 
CS therapy (EoE on steroids) and patients following CS withdrawal (EoE off 
steroids). The study has been approved by the Cantonal Ethics Committee of 
Aargau/Solothurn. Written informed consent was obtained from all patients prior to 
enrollment in the study. 
 
IgE measurements 
Serum samples stored at -20°C were available from 15 EoE naive, 33 CS-treated 
and 19 control patients. Serum levels of total IgE and specific IgE to Candica 
albicans were measured using ImmunoCAP (Thermo Fisher Scientific, Uppsala, 
Sweden) according to the manufacture’s protocol. 
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Esophageal specimens 
Biopsies from 21 patients taken for diagnosis or follow-up of EoE, were analyzed 
(EoE naive: n=9; EoE on steroids: n=6; EoE off steroids (for mean 14 months, range 
1-33 months): n=6). Because of the patchy nature of EoE, eight biopsies from the 
proximal and distal esophagus (each n=4) were analyzed. Normal tissue was 
obtained from nine patients without esophageal diseases undergoing diagnostic 
endoscopy.  
 
Immunofluorecence staining 
Tissues were fixed in 4% formaldehyde and paraffin-embedded. Cellular infiltration 
and cytokine expression were analyzed by immunofluorescence techniques as 
described previously (13, 18) using antibodies directed against eosinophil 
peroxidase (EPX; Lee Laboratory, Mayo Clinic, AZ, USA), mast cell tryptase (MCT), 
CD1a (Langerhans cells) (both Dako, Glostrup, Denmark), lympho-epithelial Kazal-
type-related inhibitor (LEKTI), cathelicidin LL-37, human beta-defensin (HBD)-3 (all 
from Novus Biologicals, Littleton, CO, USA), thymic stromal lymphopoietin (TSLP), 
kallikrein (KLK) 7 (both from Santa Cruz Biotechnology, Santa Cruz, CA, USA), 
KLK5 (Sigma Life Science, St.Louis, MO, USA), filaggrin, claudin, E-cadherin, and 
desmoglein-1 (all from Abcam, Cambridge, UK). Appropriate secondary antibodies 
labelled with Alexa Fluor 488 (Life Technologies, Thermo Fisher Scientific, Carlsbad, 
CA, USA) were applied. DNA was visualized with propidium iodide (PI: Molecular 
probes, Eugene, OR, USA). Evaluation was performed using a confocal laser 
scanning microscope (LSM 510; Carl Zeiss Jena GmbH, Jena, Germany). Cells 
were counted in five fields of highest inflammatory activity per biopsy corresponding 
to a total of 40 fields per patient at a magnification x630. To quantify the intensity of 
LEKTI, TSLP, KLK5, KLK7, LL-37, HBD-3, filaggrin, claudin-1, desmoglein and 
cadherin expression, Imaris software version 8.2.0 (Bitplane, Zurich, Switzerland) 
was used. 
 
Statistics 
Mean values with ranges for demographic variables and ±SEM for measured 
parameters are given. For comparisons between groups, t test (two groups) and 
one-way ANOVA or Kruskal-Wallis test were applied. P values < 0.05 were 
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considered statistically significant. Statistical analysis was done using Graph Pad 
software Prism 6 (La Jolla, CA, US).  
 
Results 
Increased specific IgE to Candida albicans in CS-treated patients  
The patient demographics are given in table 1. Noteworthy are the predominance of 
males, the younger age of EoE patients as compared with control patients 
(p=0.0175) and the slightly shorter disease duration in EoE patients without any CS 
therapy as compared to CS-treated patients. All patients with EoE and the majority of 
patients of the control group had been treated with PPI. EoE patients more 
frequently had concomitant atopic diseases. Accordingly, the total IgE serum levels 
were higher in EoE patients than in controls (p=0.0059) (Figure 1). Specific IgE to 
Candida at serum levels >0.35 kU/l were found in 7/33 EoE patients treated with CS, 
but not in patients of the CS-naïve EoE or control groups (Supplementary table S1). 
When we analyzed the absolute levels of IgE to Candida that were detectable in 
46/48 EoE patients and 15/19 controls, we found significantly higher levels in EoE 
patients treated with CS (p=0.0046), suggesting an increased risk of Candida 
albicans sensitization upon CS therapy (Figure 1).  
 
Reduced inflammation in CS-treated EoE 
Eosinophil infiltration is the characteristic histologic feature of EoE (1) and thus high 
numbers of eosinophils were found in patients with active, CS-naive EoE (Figure 2). 
In patients under CS therapy, eosinophil numbers were significantly reduced. Mast 
cells were also significantly elevated in CS-naïve EoE as compared with CS-treated 
EoE and controls (Figure 2). We noted a significant decrease of CD1a+ cell numbers 
toward levels below that of controls in EoE patients treated with CS. Whereas 
CD1a+ cells were observed in basal and suprabasal layers of the esophageal 
epithelium in control specimens, in CS-naïve EoE they were found in all layers 
conglomerated in clusters (Figures 2 and 4B). 
TSLP is produced by epithelial cells on surfaces exposed to the environment 
upon stimulation via protease-activated receptor (PAR)-2 and toll-like receptors 
(TLR), as well as after mechanical injury; this is believed to drive T-helper 2 type 
inflammation (19). The expression of TSLP was significantly increased in CS-naive 
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EoE patients. The low TSLP expression in CS-treated patients suggested direct or 
indirect effects of CS on TSLP production via suppression of inflammation. 
 
Reduced expression of cathelicidin and HBD in CS-treated EoE 
Next, we were interested in the expression of antimicrobial peptides such as 
cathelicidin LL-37 and human beta-defensin (HBD)-3 that have been shown to exert 
candidacidal and immunostimulatory effects (20-22). In patients with active, CS-
naïve EoE, the expression of cathelicidin was significantly increased when compared 
to CS-treated EoE and controls (p=0.0003) (Figure 3). Noteworthy is the observation 
that EoE patients on CS therapy had significantly less cathelicidin expression than 
CS-naive patients. Furthermore, we observed a significantly reduced HBD-3 
expression by epithelial cells in EoE as compared to controls (p<0.0001) that was 
still further reduced in CS-treated patients (Figure 3). 
 
Low protease inhibitor, but high protease expression, in EoE; partial 
correction with CS treatment 
A balance between proteases and their inhibitors is essential for epithelial 
homeostasis and barrier function (23, 24). A reduced expression of filaggrin that is 
cleaved by serine proteases under the control of LEKTI (23), in EoE has previously 
been reported (13). Our results confirm the significantly lower expression of filaggrin 
in EoE as compared to controls (Figure 3). Interestingly, CS therapy did not have 
any effect on the filaggrin expression, thus suggesting that lowered filaggrin 
expression was owing to an effect of the disease rather than a consequence of 
therapy.  
In agreement with previous observations (13), we found significantly 
decreased expression of LEKTI in CS-naive EoE as compared to controls (Figure 3). 
In EoE patients with CS therapy, a slight increase of LEKTI was noted, suggesting 
that CS, most likely by confining the inflammation locally, augments LEKTI 
expression. In the opposite direction from LEKTI effects, we observed an increased 
expression of the proteases KLK5 and KLK7 in EoE patients, in particular in CS-
naive EoE patients, as compared to controls.  
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Decreased expression of intercellular junction proteins in EoE; no effect of CS 
The complex system of intercellular junctions such as tight and adherence junctions, 
as well as desmosomes, is crucial for the epithelial barrier function (9). We studied 
the expression of intercellular junction proteins and observed a significantly 
decreased expression of E-cadherin (p=0.0076), claudin (p<0.0001), occludin 
(p<0.0001) and desmoglein-1 (p<0.0001) in EoE compared to control esophagus 
specimens (Figure 4). CS therapy did not have any effect on the expression of 
intercellular junction proteins, suggesting a disease-immanent low expression of 
these barrier components in EoE.  
Furthermore, we observed sparse occludin adherens junctions in the upper 
epithelial layers of EoE specimens. In CS-naive EoE, but not CS-treated EoE, 
dendrites of LHC reached to this level and penetrated between cells. In normal 
esophagus only few LHC were found in the basal layers, separate from occludin 
which was abundantly distributed on epithelial cells in the upper layers (Figure 4B).  
 
 
Discussion 
Based on the observation that EoE patients were frequently sensitized to Candida 
albicans, we aimed to identify predisposing conditions and to investigate the 
composition of the esophageal epithelial barrier in patients with and without CS 
therapy. This study has revealed an increased expression of the antimicrobial 
peptide cathelicidin, but reduced HBD3, a decreased expression of LEKTI, while that 
of the proteases KLK5 and KLK7 was increased. Furthermore, we found a 
significantly lower expression of junctional proteins E-cadherin, claudin, occludin and 
desmoglein-1 in EoE patients as compared to controls. Strikingly, in CS-treated EoE 
patients, the number of LHC was below that found in controls, and cathelicidin 
expression was lower than in CS-naive EoE.   
Most patients with EoE have elevated total IgE levels and associated atopic 
diseases (4). However, the preponderance of patients with elevated IgE levels 
(>0.35 kU/l) and the high mean levels of IgE specific for Candida albicans in EoE 
patients that had been treated with CS, were striking findings. In amendment with 
previously published data on Candida albicans sensitization in pediatric and adult 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
EoE patients (5, 6), the results of this study suggest CS therapy as an additional risk 
factor for Candida albicans sensitization.  
 
In several trials, CS therapy has been shown to improve clinical and 
endoscopic signs as well as symptoms in most EoE patients (17, 25, 26). 
Accordingly, we observed less inflammation as reflected by low numbers of 
eosinophils and mast cells as well as TSLP expression in the esophageal tissue in 
patients under current or previous CS therapy. The number of LHC was significantly 
reduced in CS-treated as compared to CS-naïve patients with EoE. CS have been 
reported to affect the viability, maturation and immune function of epidermal LHC 
that are potent antigen-presenting cells and are required for an efficient T cell 
response to Candida albicans (27-29). In atopic dermatitis, activated LHC were 
shown to penetrate the tight junctions and were likely able to capture antigens from 
the outside (30). A similar observation was made in CS-naive EoE, but not CS-
treated EoE. To summarize, CS therapy might directly affect LHC and thus promote 
Candida albicans infection and subsequent sensitization. 
 
Cathelicidin LL-37 and HBD-3 exert antimicrobial activities against Candida 
albicans by inhibiting adhesion, disrupting its cell membrane, and initiating further 
immune responses (20, 21, 31). HBD-3 that was found to be highly expressed in 
normal esophagus (32) was decreased in all EoE patients, even in those treated with 
CS, in agreement with previous observations (33). Cathelicidin was highly expressed 
in specimens of CS-naive patients, but less so in tissues of CS-treated patients. 
These findings suggest an increased cathelicidin production in EoE that is reduced 
upon corticosteroid therapy. Thus, CS are assumed to inhibit antimicrobial peptide, 
in particular cathelicidin, production resulting in a reduced antimicrobial defense at 
the esophageal epithelial surface followed by a colonization and infection by Candida 
albicans.  
 
The minor expression of filaggrin in the esophagus compared to skin (13) was 
further reduced in EoE tissue irrespective of CS therapy. The expression of both 
filaggrin and zonula occludens-3 were shown to negatively correlate with spongiosis 
in EoE (15). Recently, a deficit of the protease inhibitor LEKTI was shown to 
increase protease activity that might result in PAR-2 activation, subsequent TSLP 
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production, the influx of eosinophils and mast cells and atopic dermatitis-like lesions 
(34). Our results lead us to assume a similar scenario in EoE with low LEKTI, but 
increased KLK-5 and KLK-7 expression, elevated TSLP as well as eosinophil and 
mast cell infiltration of the esophagus. A dysregulated KLK expression has been 
demonstrated in esophageal epithelial cells exposed to IL-13 and in EoE (35).  
 
The significantly reduced expression of the tight and adherens junction 
proteins E-cadherin, claudin and occludin as well as desmoglein-1 in EoE as 
compared to non-inflamed control esophagus, suggested a defective expression 
owing to the disease rather than CS therapy. Even so, the expression was similar in 
CS-naive and CS-treated EoE assuming that reducing inflammation by CS had no 
effect on these barrier proteins. The discrepancy to recently reported normal 
desmoglein-1 expression in inactive EoE might be due to the selection of patients 
and the protocol for staining analysis (36). The impact of a decreased desmoglein-1 
expression on the impaired epithelial barrier structure and function in EoE has been 
demonstrated (11). These authors did not observe a decreased expression of tight 
and adhesion junction proteins in active EoE (11), in contrast to our findings and 
those of others (12, 15). Recently, an increased expression of genes encoding for 
desmoglein-1 and filaggrin upon therapy with fluticasone or elemental diet in 
association with an improved functional esophageal mucosal integrity has been 
reported (37, 38). Notably, Candida albicans itself may contribute to tissue damage 
by secreting aspartic proteinases that detaches intercellular junctions such as 
desmosomes (39) and by enhancing the degradation of E-cadherin (40, 41).  
 
Taken together, our study provided further evidence for an disease-inherent 
impaired epithelial barrier in EoE that could be only partially restored in patients 
treated with CS. Thus, we hypothesize the following scenario: A decreased 
expression of LEKTI leads to an increased activity of KLK5 and KLK7 that, by 
activating the PAR2 receptor on epithelial cells, induces TSLP production. In addition 
to kallikreins, a decreased expression of intercellular adhesion proteins results in a 
defective epithelial structure. The impaired epithelial barrier promotes the 
colonization by Candida albicans that further detaches junction proteins and thus 
assists microbial invasion followed by innate and adaptive immune responses. TSLP 
is able to stimulate eosinophils to generate extracellular DNA traps that directly kill 
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microbes, but may also initiate a T helper type 2 inflammation involving dendritic 
cells, T cells and B cells and subsequent sensitization to Candida albicans. CS seem 
to have selective effects on improving the epithelial barrier. Instead, CS reduce the 
expression of cathelicidin as well as the numbers of LHC and eosinophils, thereby 
possibly even further promoting Candida albicans colonization and invasion.  
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Tables 
Table 1   Patients characteristics and serum IgE levels 
 CS-naïve EoE CS-treated 
EoE 
Controls Statistical 
significanc
e 
 n % n % N % P 
Patients 15  45  20   
Male gender  15 100 35 78 1 5 <0.0001 
 Mean Range Mean Range Mean Range  
Age in years (mean, range) 43 17-67 43 18-83 53 29-78 0.0175 
Time until diagnosis (years) 7 1-21 9 1-39    
        
 n % n % n %  
History of atopic diseases        
All 8 53 33 73 5 25 0.0011 
Allergic rhinitis 4 27 25 56 3 15  
Bronchial asthma 4 27 18 40 0 0  
Atopic dermatitis 1 7 1 2 0 0  
Food allergy 1 7 12 27 2 10  
Symptoms         
Dysphagia 13 87 43 96 6 30  
Reflux 5 33 23 51 13 65  
Chest pain 13 87 45 100 7 35  
Epigastric pain 1 7 4 9 12 60  
Selflimited food impaction 6 40 19 42 0 0  
Previous therapy         
    Corticosteroids 0 0 45 100 0 0  
    Proton pump inhibitors 10 67 35 78 13 65  
    Endoscopic bolus removal 6 40 16 36 0 0  
    Dilatation 2 13 18 40 0 0  
        
 Mean Range Mean Range Mean Range  
Serum IgE levels        
Total IgE 204.4 
 
9.35-
1118 
333.3 5.25-
6067 
38.91 1.2-
229.5 
0.0059 
IgE to Candida albicans 0.083 0.01 - 
0.34 
0.49 0 – 
6.88 
0.025 0 - 0.2 0.0046 
Patients with IgE to Candida 
albicans >0.35 kU/l 
0  7  0   
Detection of Candida albicans        
Histology 0  2  0   
Endoscopy 1  3  0   
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Figure legends 
 
Figure 1 Levels of total IgE and Candida albicans-specific IgE. Bars represent 
mean values (+SEM) of serum IgE of EoE patients without (black, n=15) or with 
corticosteroid therapy (grey, n=33) compared to controls (white, n=19). *, p<0.05; **, 
p<0.01. 
 
Figure 2 Eosinophilic inflammation is striking in corticosteroid (CS)-naive, but 
reduced in CS-treated EoE patients. The graphs show mean numbers (+SEM) of 
eosinophils, mast cells, and Langerhans (CD1a+) cells as well as expression of 
TSLP in esophageal biopsy specimens of CS-naive (n=9), CS-treated (n=6), 
previously CS-treated (n=6) EoE patients and controls (n=9). *, p<0.05; **, p<0.01; 
***, p<0.001; ****, p<0.0001. Representative images of immunofluorescence staining 
are shown. Magnification x630 (cells), x400 (TSLP), bars 20 μm. 
 
Figure 3 Abnormal expression of antimicrobial peptides, filaggrin, proteases and 
protease inhibitor in EoE. The graphs show mean (+SEM) expression of cathelicidin, 
HBD3, filaggrin, LEKTI, KLK5 and KLK7 in esophageal biopsy specimens of CS-
naïve (n=9), CS-treated (n=6), previously CS-treated (n=6) EoE patients and controls 
(n=9). Representative images of immunofluorescence staining are given. 
Magnification x400, bars 20 μm. 
 
Figure 4 Abnormal expression of junctional proteins in EoE. Graphs in panel A 
show mean (+SEM) expression of E-cadherin, claudin, occludin and desmoglein-1 in 
esophageal biopsy specimens of CS-naïve (n=9), CS-treated (n=6), previously CS-
treated (n=6) EoE patients and controls (n=9). Representative images of 
immunofluorescence staining are shown. Magnification x400, bars 20 μm. Panel B 
shows Langerhans cells (LHC, CD1a+, green) in basal and abundant occludin in 
upper epithelial layer in controls, but few LHC and scarce occludin expression in CS-
treated EoE. In CS-naive EoE, LHC are spread through the entire epithelium and 
their dendrites penetrate the upper cell layers between tight junctions (occludin, red) 
(insert). Magnification x1000. 
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